Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26094097 | 0.92 | CRBN (0.52) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL26095175 | 0.92 | CRBN (0.52) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL31033918 | 0.92 | CRBN (0.52) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL31033869 | 0.92 | CRBN (0.52) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL30351971 | 0.85 | CRBN (0.49) | CRBNDDB1IKZF3 | |
| SCHEMBL31033567 | 0.85 | CRBN (0.58) | CRBNIKZF1TNFIL1BDDB1 | |
| SCHEMBL31034187 | 0.85 | CRBN (0.47) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL31034315 | 0.83 | CRBN (0.47) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL31034297 | 0.83 | CRBN (0.47) | CRBNIKZF2IKZF1CSNK1A1BRD4 | |
| SCHEMBL31034225 | 0.82 | CRBN (0.59) | CRBNIKZF2IKZF1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243210-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADER DEVELOPED BASED THEREON AND THEIR APPLICATIONS | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-07-31 | — | — | US | claimed |
| EP-4421071-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-08-28 | — | — | EP | claimed |
| US-20250243210-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADER DEVELOPED BASED THEREON AND THEIR APPLICATIONS | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243210-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADER DEVELOPED BASED THEREON AND THEIR APPLICATIONS | CRBN, MDM2, CBLB | CRBN 1/4885IKZF2 2356/4885IKZF1 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.